Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)STU:H7T1 72 EV-to-FCF is 73.40 as of Aug. 05, 2026. GuruFocus rates STU:H7T1 with a GF Score™ of 72/100 and a GF Value™ of €11.20 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 571 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 82.49% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HUTCHMED (China)'s Enterprise Value is €630.4 Mil.
HUTCHMED (China)'s Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €8.6 Mil. Therefore, HUTCHMED (China)'s EV-to-FCF for today is 73.40.
The historical rank and industry rank for HUTCHMED (China)'s EV-to-FCF or its related term are showing as below:
STU:H7T1'
s EV-to-FCF Range Over the Past 10 Years
Min: -324.21 Med: -47.3 Max: 78.18
Current: 78.18
During the past 13 years, the highest EV-to-FCF of HUTCHMED (China) was 78.18. The lowest was -324.21. And the median was -47.30.
STU:H7T1's EV-to-FCF is ranked worse than 82.49% of 571
companies
in the Drug Manufacturers industry
Industry Median: 21.2
vs STU:H7T1: 78.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HUTCHMED (China)'s PE Ratio (TTM) for today is calculated as:
HUTCHMED (China)'s share price for today is €10.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HUTCHMED (China)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.087.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HUTCHMED (China) EV-to-FCF Related Terms
HUTCHMED (China) EV-to-FCF Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s EV-to-FCF falls into.
HUTCHMED (China)'s current Enterprise Value is €630.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HUTCHMED (China)'s Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €8.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (STU:H7T1) has a EV-to-FCF of 73.40 as of Aug. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #471 out of 571 companies in the Drug Manufacturers industry, placing it in the top 82.5%.
Is HUTCHMED (China)'s EV-to-FCF too high?
HUTCHMED (China)'s current EV-to-FCF is 73.40. The Drug Manufacturers industry median EV-to-FCF is 21.20. HUTCHMED (China)'s value of 73.40 is 246.2% above this industry median. Based on the distribution chart, HUTCHMED (China) ranks #471 out of 571 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #471 out of 571 companies for EV-to-FCF. This places HUTCHMED (China) in the lower half of its industry. The industry median EV-to-FCF is 21.20. HUTCHMED (China)'s value of 73.40 is 246.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.20, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current EV-to-FCF of 73.40 is 246.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current EV-to-FCF is 73.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (STU:H7T1) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.20, compared to a current price of €10.00 — trading 10.7% below its estimated fair value. The current EV-to-FCF is 73.40 and 246.2% above the Drug Manufacturers industry median of 21.20. HUTCHMED (China)'s overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For HUTCHMED (China) (STU:H7T1), the current EV-to-FCF is 73.40 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (STU:H7T1) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of €10.00 is trading 10.7% below its estimated GF Value™ of €11.20.
GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.
Key valuation signals for STU:H7T1:
EV-to-FCF: 73.40
GF Value™: €11.20 vs. price of €10.00 (10.7% below fair value)
Industry Position: 246.2% above the Drug Manufacturers median (#471 of 571)
No single metric tells the full story. See the STU:H7T1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
72GF Score
Get the complete analysis for STU:H7T1
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:H7T1 has been successfully added to your 
